Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/8/2019
SIETES contiene 92797 citas

 
 
 1 a 20 de 48 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Wei L, Lai EC-C, Kao-Yang Y-H, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5a-reductase inhibitors: population based cohort study. BMJ 2019;365:10 de abril. [Ref.ID 103112]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Gill SS, Bai AD. Beta testing the potential link between the alpha antagonist tamsulosin and dementia. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102635]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Duan Y, Grady JJ, Albertsen PC, Wu ZH. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102634]
5. Cita con resumen
Welk B, McArthur E, Fraser L-A, Hayward J, Dixon S, Hwang YJ, Ordon M. The risk of fall and fracture with the initiation of a prostate-selective a antagonist: a population based cohort study. BMJ 2015;351:h5398. [Ref.ID 99576]
6. Cita con resumen
Anónimo. Incontinences urinaires d'origine médicamenteuse. Prescrire 2015;35:271-4. [Ref.ID 99126]
7. Cita con resumen
McCartney M. How the UK regulator became the herbalists' marketeer. BMJ 2014;348:g3194. [Ref.ID 98013]
8. Cita con resumen
Anónimo. Tadalafil (Cialis) et hypertrophie bénigne de la prostate. Prescrire 2013;33:886-7. [Ref.ID 96715]
10. Cita con resumen
Anónimo. An introduction to patient decision aids. Drug Ther Bull 2012;50:90-2. [Ref.ID 93521]
11. Cita con resumen
Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT, Hudson M. Cholestasis secondary to anabolic steroid use in young men. BMJ 2012;344:47-9. [Ref.ID 92357]
12. Cita con resumen
Anónimo. Tadalafil (Cialis) for signs and symptoms of benign prostatic hyperplasia. Med Lett Drugs Ther 2011;53:89-90. [Ref.ID 91824]
13. Cita con resumen
Wuerstle MC, Van Den Eeden SK, Poon KT, Quinn VP, Hollingworth JM, Loo RK, Jacobsen SJ, for the Urologic Diseases in America Project. Contribution of common medications to lower urinary tract symptoms in men. Arch Intern Med 2011;171:1680-2. [Ref.ID 91542]
14. Cita con resumen
Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster Jr HE, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT, for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms. A randomized trial. JAMA 2011;306:1344-51. [Ref.ID 91218]
15.Tiene citas relacionadas
D'Amico AV. Risk-based management of prostate cancer. N Engl J Med 2011;365:169-71. [Ref.ID 90833]
16.Tiene citas relacionadas Cita con resumen
Theoret MR, Ning Y-M, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5a-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365:97-9. [Ref.ID 90829]
17.Tiene citas relacionadas Cita con resumen
Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease. Arch Intern Med 2011;171:920-2. [Ref.ID 90625]
18.Tiene citas relacionadas Cita con resumen
Stephenson A, Seitz D, Bell CM, Gruneir A, Gershon AS, Austin PC, Fu L, Anderson GM, Rochon PA, Gill SS. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease. A population-based study. Arch Intern Med 2011;171:914-20. [Ref.ID 90624]
19. Cita con resumen
Anónimo. Subgrupos ATC y principios activos de mayor consumo en el Sistema Nacional de Salud en 2009. Inf Ter Sist Nac Salud 2010;34:89-92. [Ref.ID 89981]
20.Tiene citas relacionadas Cita con resumen
Swerdloff RS, Wang C. Dihydrotestosterone: hormone or autocrine-paracrine signal?. Ann Intern Med 2010;153:678-9. [Ref.ID 89658]
Seleccionar todas
 
 1 a 20 de 48 siguiente >>